On Monday, AbbVie Inc (NYSE:ABBV) and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.
“Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,” said Robert Michael, CEO of AbbVie.
Also Read: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors.
Amylin, a satiety hormone, has been identified as a potential therapeutic target for obesity, given its role in activating signals to …
